Abstract：【Objective】To investigate the clinical efficacy of irbesartan hydrochlorothiazide combined with the Jingui Shenqi Pill in the treatment of hypertensive chronic heart failure (CHF) and its impact on the nucleotide binding oligomerization domain-like receptor protein 3 (NLRP3)/nuclear factor B (NF-κB) pathway. 【Methods】A total of 106 hypertensive CHF patients admitted to our hospital from May 2019 to May 2022 were randomly divided into an observation group (treated with irbesartan hydrochlorothiazide combined with the Jingui Shenqi Pill) and a control group (treated with irbesartan hydrochlorothiazide) using a random number table method,with 53 patients in each group. We compared the efficacy,traditional Chinese medicine syndrome scores,blood pressure levels,cardiac function [B-type brain natriuretic peptide (BNP),left ventricular ejection fraction (LVEF),left ventricular end diastolic diameter (LVEDD),left ventricular end systolic diameter (LVESD)],NLRP3/NF-κB pathway [NLRP3,NF-κB,interleukin-1 (IL-1β),interleukin-18 (IL-18),tumor necrosis factor-α(TNF-α)],and safety between two groups. 【Results】The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant (P<0.05); After treatment,the observation group had lower scores of traditional Chinese medicine syndromes such as chest tightness,palpitations,difficulty lying flat,lower limb edema,palpitations,dizziness,tinnitus,lack of qi and lazy speech,fatigue and fatigue compared to the control group (P<0.05); After treatment,the systolic and diastolic blood pressure in the observation group were lower than those in the control group (P<0.05); After treatment,BNP,LVEDD,and LVESD in the observation group were lower than those in the Western medicine group,while LVEF was higher than that in the control group (P<0.05); After treatment,the NLRP3,NF-κB,IL-1β,IL-18,and TNF-α levels in the observation group were lower than those in the control group (P<0.05); There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). 【Conclusions】The combination of Irbesartan Hydrochlorothiazide and the Jinkui Shenqi Pill in the treatment of hypertensive CHF can effectively improve clinical symptoms and signs,lower blood pressure levels,improve cardiac function,inhibit NLRP3/NF-κB pathway activation,and is safe and reliable.
王文静. 厄贝沙坦氢氯噻嗪联合金匮肾气丸治疗高血压慢性心力衰竭患者的临床效果及对NLRP3/NF-κB通路的影响[J]. 医学临床研究, 2023, 40(8): 1225-1228.
WANG Wen-jing. Effect of Irbesartan Hydrochlorothiazide Combined with Jinkui Shenqi Pill on Hypertensive CHF and its Influence on NLRP3/NF-κB Pathway. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1225-1228.
2023, Vol. 40 
